NAV

Isoxicam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Isoxicam
DrugBank Accession Number
DB08942
Background

Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 335.335
Monoisotopic: 335.057591231
Chemical Formula
C14H13N3O5S
Synonyms
  • Isoxicam
  • Isoxicamo
  • Isoxicamum
External IDs
  • W 8495
  • W-8495
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirIsoxicam may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Abciximab.
AcebutololIsoxicam may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Isoxicam.
AcemetacinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Maxicam

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Alpha amino acids and derivatives / Organosulfonamides / Benzenoids / 1,2-thiazines / Vinylogous acids / Isoxazoles / Heteroaromatic compounds / N-acylimines / Oxacyclic compounds / Azacyclic compounds
show 4 more
Substituents
Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzothiazine / Carbonyl group / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, isoxazoles, benzothiazine (CHEBI:76163)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
8XU734C4NG
CAS number
34552-84-6
InChI Key
YYUAYBYLJSNDCX-UHFFFAOYSA-N
InChI
InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)
IUPAC Name
4-hydroxy-2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O

References

General References
  1. Fenner H: Comparative biochemical pharmacology of the oxicams. Scand J Rheumatol Suppl. 1987;65:97-101. [Article]
  2. DiPasquale G, Rassaert C, Richter R, Welaj P, Gingold J, Singer R: The anti=inflammatory properties of isoxicam (4-hydroxy-2methyl-N-(5-methyl-3isoxolyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide). Agents Actions. 1975 Aug;5(3):256-63. [Article]
  3. Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 [Link]
KEGG Drug
D04639
PubChem Compound
54677972
PubChem Substance
310264909
ChemSpider
10442695
ChEBI
76163
ChEMBL
CHEMBL53292
ZINC
ZINC000049538599
PharmGKB
PA166049183
PDBe Ligand
ICD
Wikipedia
Isoxicam
PDB Entries
4m10

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.213 mg/mLALOGPS
logP2.61ALOGPS
logP0.77Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.36Chemaxon
pKa (Strongest Basic)-0.71Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area112.74 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity85.79 m3·mol-1Chemaxon
Polarizability32.38 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-004r-3911000000-ea33aeb4c6cdbcd42af1
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0hi2-4920000000-6d8f0aecb48174d3dfd1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-5029000000-9878c3e1ce911a0b96b3
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-006t-1950000000-61f91d6438adc458384f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0036-9211000000-7bc94d09b7c4254a6e97
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-4930000000-3f97ea5dd80ec6daa462
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9653000000-fc482cd676d6a869b364
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01oy-8891000000-b006e398c3802d3a7407
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-179.0243491
predicted
DarkChem Lite v0.1.0
[M-H]-163.50581
predicted
DeepCCS 1.0 (2019)
[M+H]+177.9758491
predicted
DarkChem Lite v0.1.0
[M+H]+165.86423
predicted
DeepCCS 1.0 (2019)
[M+Na]+179.5037491
predicted
DarkChem Lite v0.1.0
[M+Na]+171.95738
predicted
DeepCCS 1.0 (2019)

Drug created at May 26, 2014 22:17 / Updated at February 21, 2021 18:52